Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 45 results found. Search for [ Pfizer COVID-19 vaccine safety study india ]

Results 1 to 21 of 45
Rashi Bisaria
New Delhi, January 14, 2021
Pfizer must conduct local study for vaccine approval: VK Paul Any vaccine maker, including Pfizer, which has sought emergency-use authorisation for its Covid-19 shot in India, must conduct a local \"bridging\" safety and immunogenicity study to be considered for the country's immunisation programme, a senior government official told Reuters. Serum Institute of India, the local manufacturer of the vaccine developed by AstraZeneca and Oxford University, has done a similar study on more than 1...


Reuters
January 14, 2021
As of now, the pre-condition for any vaccine to be implemented in India is that you have to do a bridging trial, said Niti Aayog member VK Paul who also heads National Expert Group On Vaccine Administration for COVID-19 (NEGVAC)


Rajeev Dubey | Vivek Punj
January 11, 2021
Full authorisation-better known as \"full pre-qualification\"-is a pre-requisite to sell the vaccine in the open market or for mass immunisation of healthy individuals who are not frontline workers


BusinessToday.In
December 24, 2020
Coronavirus vaccine trials: Earlier officials had said that people are unwilling to participate in the exercise thinking why take part in the trials when the vaccine would soon be available for everybody


BusinessToday.In
December 22, 2020
If needed, the company could provide a new vaccine technically within six weeks to deal with the new mutated strain detected in Britain, says BioNTech CEO Ugur Sahin


Reuters
December 12, 2020
 India readies for 60 crore doses of Covid-19 vaccines to be administered to the most vulnerable people through conventional cold chain systems, says top government expert


Ankita Chakravarti
New Delhi, December 10, 2020
Pharmaceutical giant Pfizer Inc has revealed that some of the data it had submitted to Europe's top drug regulator had been accessed by hackers.


BusinessToday.In
December 10, 2020
The Subject Expert Committee (SEC), a government panel tasked with vetting coronavirus vaccines, has asked Bharat Biotech and Serum Institute of India (SII) to submit updated country-specific trial data of their vaccine candidates Covaxin and Covishield


Joe C Mathew
December 7, 2020
Both companies have applied for vaccine approval, following which, these companies will be able to supply vaccines to the central government to begin its multi-phase vaccination of Indian residents against the COVID-19


PB Jayakumar
December 4, 2020
The company is also working with the USFDA to start an Investigational New Drug (IND) application for Pegylated Interferon alpha-2b in order to initiate clinical trials in US


BusinessToday.In
December 4, 2020
India Stock Market Highlights Today: During the session, Sensex touched a lifetime high of 45,148 and Nifty hit an all-time high of 13,280


Associated Press
November 30, 2020
Multiple vaccine candidates must succeed for the world to stamp out the pandemic, which has been on the upswing in the US and Europe. US hospitals have been stretched to the limit as the nation has seen more than 160,000 new cases per day


BusinessToday.In
November 27, 2020
After the publication of early data from phase-3 clinical trials, drugmakers Pfizer and BioNTech have sought regulatory approval to deploy their inoculation under emergency-use rules. American biotech company Moderna is also likely to do the same soon


PB Jayakumar & Joe C Mathew
New Delhi, November 25, 2020
A blow-by-blow account of how Indian vaccines are being readied


BusinessToday.In
November 23, 2020
The study found that patients of confirmed COVID-19 with moderate symptoms were discharged from hospital earlier than those patients that did not receive Favipiravir, with the median time to clinical cure reduced by 2.5 days compared with the control group.


BusinessToday.In
November 22, 2020
Bharat Biotech has started the phase- 3 trial of its potential COVID-19 vaccine, involving 26,000 volunteers this month across 25 centres in the country, including Hyderabad, Goa, Nagpur, Bhubaneswar, and Aligarh


BusinessToday.In
November 21, 2020
Pfizer's CEO Albert Bourla confirmed the company's application and said in a video statement,  'It is with great pride and joy - and even a little relief - that I can say that our request for emergency use authorization for our COVID-19 vaccine is now in the FDA's hands.'


BusinessToday.In
November 21, 2020
Pfizer that its EUA submission is supported by solicited safety data from a randomised subset of approximately 8,000 participants aged 18 years or above and unsolicited safety data from approximately 38,000 trial participants


Manoj Sharma
November 18, 2020
Pfizer says Phase 3 study of their COVID-19 vaccine candidate met \"all primary efficacy endpoints\".  During its early analysis, vaccine had shown 90 per cent efficacy but final analysis involving 170 confirmed cases of COVID-19 showed 95 per cent efficacy


Manali
November 18, 2020
Defining the four attributes, Serum Institute of India CEO Adar Poonawalla posted that a good vaccine must be safe, should offer long-term protection against targeted disease, can be transported and stored at a manageable temperature, and lastly, affordable


PAGES 1 OF 3  123